- Trials with a EudraCT protocol (44,399)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,399 result(s) found.
Displaying page 2,139 of 2,220.
| EudraCT Number: 2010-024604-10 | Sponsor Protocol Number: S52898 | Start Date*: 2011-03-18 | ||||||||||||||||
| Sponsor Name:UZ Gasthuisberg Leuven | ||||||||||||||||||
| Full Title: An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escala... | ||||||||||||||||||
| Medical condition: Polycystic liver disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-000541-41 | Sponsor Protocol Number: N/A | Start Date*: 2021-04-22 | |||||||||||
| Sponsor Name:Oslo University Hospital | |||||||||||||
| Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial | |||||||||||||
| Medical condition: SARS-CoV-2- infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005458-27 | Sponsor Protocol Number: MK-4830-002 | Start Date*: 2022-04-28 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer | |||||||||||||
| Medical condition: First-line treatment of advanced High Grade Serous Ovarian Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001998-24 | Sponsor Protocol Number: ME3827/1-1 | Start Date*: 2014-10-09 |
| Sponsor Name:Saarland University | ||
| Full Title: A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5... | ||
| Medical condition: Preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants. | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003407-35 | Sponsor Protocol Number: SL0044 | Start Date*: 2022-03-09 | |||||||||||
| Sponsor Name:UCB Biopharma SRL | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active... | |||||||||||||
| Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) BE (Prematurely Ended) FR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) PT (Prematurely Ended) AT (Completed) DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002638-18 | Sponsor Protocol Number: 20190288 | Start Date*: 2021-10-14 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment | |||||||||||||
| Medical condition: KRAS p.G12C mutant untreated stage IV Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended) DE (Temporarily Halted) BE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) DK (Prematurely Ended) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-004908-36 | Sponsor Protocol Number: RAD001A B253 E03 | Start Date*: 2007-01-10 |
| Sponsor Name:Novartis Farmaceútica S.A | ||
| Full Title: Extension E-03 al Protocolo nº RAD001AB253 Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la med... | ||
| Medical condition: Trasplante cardiaco de novo | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-003279-38 | Sponsor Protocol Number: TZP-101-CL-G004 | Start Date*: 2007-08-17 |
| Sponsor Name:Tranzyme Inc. | ||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G... | ||
| Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-005356-25 | Sponsor Protocol Number: 12712A | Start Date*: 2016-07-27 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age | |||||||||||||
| Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) DE (Completed) HU (Completed) PL (Completed) IT (Prematurely Ended) ES (Completed) BG (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001623-44 | Sponsor Protocol Number: IRON-CRT-001 | Start Date*: 2017-06-15 | |||||||||||
| Sponsor Name:Ziekenhuis Oost Limburg (ZOL), Genk | |||||||||||||
| Full Title: Effect of Intravenous Ferric Carboxymaltose on reverse remodeling following Cardiac Resynchronization therapy | |||||||||||||
| Medical condition: Heart failure with reduced left ventricular ejection fraction | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004496-31 | Sponsor Protocol Number: CNTO148UCO3003 | Start Date*: 2018-11-07 | |||||||||||
| Sponsor Name:Janssen Biologics BV | |||||||||||||
| Full Title: A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety,and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Pa... | |||||||||||||
| Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005269-15 | Sponsor Protocol Number: CO42865 | Start Date*: 2022-05-18 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER | |||||||||||||
| Medical condition: RET-mutated Medullary Thyroid Cancer (MTC) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-006486-38 | Sponsor Protocol Number: ComplexitDOC_PSI | Start Date*: 2022-08-17 |
| Sponsor Name:University of Liege | ||
| Full Title: Complexity-enhancing drugs to treat disorders of consciousness (DoC): a psilocybin study | ||
| Medical condition: Disorders of consciousness as unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) after a coma due to acquired brain injury. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-005651-17 | Sponsor Protocol Number: plexusogsirkulasjon | Start Date*: 2013-06-13 |
| Sponsor Name:Oslo Universitetssykehus | ||
| Full Title: Plexus brachialis block and circulation. Comparing effects on skin microcirculation and macro circulation of lidocain brachial plexus block with versus without epinephrine. | ||
| Medical condition: human microcirculation and haemodynamic changes (macrosirculation) in healthy volunteers. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001656-18 | Sponsor Protocol Number: INOCOV-19 | Start Date*: 2020-05-19 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Inhaled Nitric Oxide As A Bridge To Mechanical Ventilation In Patients With Suspected Covid-19 Respiratory Failure | ||
| Medical condition: Severe respiratory failure in patients with confirmed, suspected or probable Covid- 19 disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-001165-21 | Sponsor Protocol Number: CHDM201I12201 | Start Date*: 2022-02-15 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first... | |||||||||||||
| Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-005221-12 | Sponsor Protocol Number: OCTOPUS-2014 | Start Date*: 2015-09-07 | |||||||||||||||||||||
| Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||||||||||||
| Full Title: OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer | |||||||||||||||||||||||
| Medical condition: Ovarian Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-001798-21 | Sponsor Protocol Number: GS-US-558-5915 | Start Date*: 2022-01-27 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma | |||||||||||||
| Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002434-40 | Sponsor Protocol Number: AST-MOMA | Start Date*: 2012-03-23 | |||||||||||
| Sponsor Name:University Hospital Tuebingen | |||||||||||||
| Full Title: Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis Modification according to manifestation | |||||||||||||
| Medical condition: Systemic sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002585-12 | Sponsor Protocol Number: A3L00057 | Start Date*: 2020-08-03 | ||||||||||||||||
| Sponsor Name:SANOFI PASTEUR | ||||||||||||||||||
| Full Title: Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants | ||||||||||||||||||
| Medical condition: Haemophilus influenzae type b immunisation | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.